Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront

PartnershipCD19xCD3 T cell engagerPositive

AI Analysis

Summary

Novartis has entered into an exclusive worldwide licensing agreement with Abogen Biosciences for an early-stage CD19xCD3 T cell engager, paying $575 million upfront with potential milestone payments up to $7.2 billion.

Importance:7/10

Sentiment:

0.60

licensingmRNAT cell engagerimmunotherapyCD19xCD3exclusive rightsearly-stage

Related Companies

$NVS

Read the original article

Published by Endpoints News on October 2, 2026 8:55 AM

Read Original